NHL-话题@MedSci

#NHL#

18篇内容 | 2209人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2222072, encodeId=2ef222220e2cb, content=<a href='/topic/show?id=518761566e4' target=_blank style='color:#2F92EE;'>#来那度胺#</a> <a href='/topic/show?id=b46f12e81ed' target=_blank style='color:#2F92EE;'>#NHL#</a> <a href='/topic/show?id=569f4453e38' target=_blank style='color:#2F92EE;'>#奥妥珠单抗#</a>, objectTitle=【EClinicalMedicine】奥妥珠单抗联合来那度胺治疗复发难治性惰性NHL, objectType=article, longId=840071, objectId=b4bc8400e1ad, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240730/1722330274156_8538692.jpg, objectUrl=/article/show_article.do?id=b4bc8400e1ad, replyNumber=0, likeNumber=86, createdTime=2024-08-23, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=b4bc8400e1ad, moduleTitle=【EClinicalMedicine】奥妥珠单抗联合来那度胺治疗复发难治性惰性NHL, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b4bc8400e1ad)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2207023, encodeId=190f220e023a9, content=<a href='/topic/show?id=170699e5621' target=_blank style='color:#2F92EE;'>#非霍奇金淋巴瘤#</a> <a href='/topic/show?id=b46f12e81ed' target=_blank style='color:#2F92EE;'>#NHL#</a> <a href='/topic/show?id=edba4069ec' target=_blank style='color:#2F92EE;'>#CAR-T治疗#</a>, objectTitle=JAMA Oncol：综合放疗用于局限性NHL CAR-T桥接治疗的小型研究, objectType=article, longId=827862, objectId=dd0a82e862ef, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240528/1716877194938_5579292.jpg, objectUrl=/article/show_article.do?id=dd0a82e862ef, replyNumber=0, likeNumber=107, createdTime=2024-05-28, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=dd0a82e862ef, moduleTitle=JAMA Oncol：综合放疗用于局限性NHL CAR-T桥接治疗的小型研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dd0a82e862ef)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2187980, encodeId=e647218e9802f, content=<a href='/topic/show?id=10dc3890e66' target=_blank style='color:#2F92EE;'>#吉西他滨#</a> <a href='/topic/show?id=b46f12e81ed' target=_blank style='color:#2F92EE;'>#NHL#</a> <a href='/topic/show?id=fe4b1113131c' target=_blank style='color:#2F92EE;'>#BEAM/BEAC#</a>, objectTitle=【Cancer Med】NHL自体移植前预处理，含吉西他滨方案与BEAM/BEAC无差异, objectType=article, longId=813645, objectId=921c81364531, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/doctor-is-working-at-the-hospital-PTE4SCK.jpg, objectUrl=/article/show_article.do?id=921c81364531, replyNumber=0, likeNumber=99, createdTime=2024-02-18, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陕西省, moduleDTOList=[ModuleDTO(moduleId=921c81364531, moduleTitle=【Cancer Med】NHL自体移植前预处理，含吉西他滨方案与BEAM/BEAC无差异, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=921c81364531)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2187350, encodeId=26cc218e35019, content=<a href='/topic/show?id=170699e5621' target=_blank style='color:#2F92EE;'>#非霍奇金淋巴瘤#</a> <a href='/topic/show?id=b46f12e81ed' target=_blank style='color:#2F92EE;'>#NHL#</a> <a href='/topic/show?id=141d40627a' target=_blank style='color:#2F92EE;'>#CAR-T#</a>, objectTitle=【CII】赵明峰教授团队基于T细胞亚群开发预测CAR-T治疗r/r NHL反应的模型, objectType=article, longId=812763, objectId=60bc812e63bf, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/young-people-on-medical-staff-meeting-ZFY96R4.jpg, objectUrl=/article/show_article.do?id=60bc812e63bf, replyNumber=0, likeNumber=115, createdTime=2024-02-15, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陕西省, moduleDTOList=[ModuleDTO(moduleId=60bc812e63bf, moduleTitle=【CII】赵明峰教授团队基于T细胞亚群开发预测CAR-T治疗r/r NHL反应的模型, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=60bc812e63bf)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1493234, encodeId=5e9514932349d, content=<a href='/topic/show?id=b46f12e81ed' target=_blank style='color:#2F92EE;'>#NHL#</a>, objectTitle=Oncologist:老年侵袭性非霍奇金淋巴瘤（NHL）的临床结局、治疗毒性和医疗保健利用, objectType=article, longId=215721, objectId=057f215e217a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=057f215e217a, replyNumber=0, likeNumber=105, createdTime=2021-08-15, rootId=0, userName=yzh402, userId=f7839003589, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=057f215e217a, moduleTitle=Oncologist:老年侵袭性非霍奇金淋巴瘤（NHL）的临床结局、治疗毒性和医疗保健利用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=057f215e217a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1493233, encodeId=b1a31493233e7, content=<a href='/topic/show?id=b46f12e81ed' target=_blank style='color:#2F92EE;'>#NHL#</a>, objectTitle=Blood：自体移植 or 异体移植，外周T-NHL患者到底该选谁？, objectType=article, longId=205381, objectId=99b020538125, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=99b020538125, replyNumber=0, likeNumber=133, createdTime=2021-01-07, rootId=0, userName=yzh402, userId=f7839003589, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=99b020538125, moduleTitle=Blood：自体移植 or 异体移植，外周T-NHL患者到底该选谁？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=99b020538125)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1493232, encodeId=0a7c149323218, content=<a href='/topic/show?id=b46f12e81ed' target=_blank style='color:#2F92EE;'>#NHL#</a>, objectTitle=Clin Cancer Res：JWCAR029可有效且安全治疗难治性B-NHL, objectType=article, longId=201444, objectId=2095201444c5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2095201444c5, replyNumber=0, likeNumber=106, createdTime=2020-10-02, rootId=0, userName=yzh402, userId=f7839003589, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2095201444c5, moduleTitle=Clin Cancer Res：JWCAR029可有效且安全治疗难治性B-NHL, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2095201444c5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1493231, encodeId=1d21149323197, content=<a href='/topic/show?id=b46f12e81ed' target=_blank style='color:#2F92EE;'>#NHL#</a>, objectTitle=Blood：Myc对采用EPOCH±Vorinostat治疗的HIV-NHLs的预后的影响, objectType=article, longId=195143, objectId=8218195143f1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8218195143f1, replyNumber=0, likeNumber=109, createdTime=2020-06-03, rootId=0, userName=yzh402, userId=f7839003589, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8218195143f1, moduleTitle=Blood：Myc对采用EPOCH±Vorinostat治疗的HIV-NHLs的预后的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8218195143f1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1493230, encodeId=4e81149323038, content=<a href='/topic/show?id=b46f12e81ed' target=_blank style='color:#2F92EE;'>#NHL#</a>, objectTitle=Blood：Ublituximab联合Umbralisib治疗复发性/难治性B细胞NHL和CLL的安全性评估, objectType=article, longId=180400, objectId=2b0b180400c6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2b0b180400c6, replyNumber=0, likeNumber=153, createdTime=2019-10-04, rootId=0, userName=yzh402, userId=f7839003589, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2b0b180400c6, moduleTitle=Blood：Ublituximab联合Umbralisib治疗复发性/难治性B细胞NHL和CLL的安全性评估, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2b0b180400c6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1493229, encodeId=51de1493229d4, content=<a href='/topic/show?id=b46f12e81ed' target=_blank style='color:#2F92EE;'>#NHL#</a>, objectTitle=European Journal of Human Genetics：中国SNHL患者的综合遗传测试和变异解释, objectType=article, longId=181099, objectId=576018109936, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=576018109936, replyNumber=0, likeNumber=120, createdTime=2019-10-03, rootId=0, userName=yzh402, userId=f7839003589, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=576018109936, moduleTitle=European Journal of Human Genetics：中国SNHL患者的综合遗传测试和变异解释, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=576018109936)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1493228, encodeId=22b31493228e0, content=<a href='/topic/show?id=b46f12e81ed' target=_blank style='color:#2F92EE;'>#NHL#</a>, objectTitle=2019年ASCO：Umbralisib单药治疗边缘区淋巴瘤的阳性中期数据（UNITY-NHL试验）, objectType=article, longId=167755, objectId=817a16e7558a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=817a16e7558a, replyNumber=0, likeNumber=88, createdTime=2019-06-07, rootId=0, userName=yzh402, userId=f7839003589, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=817a16e7558a, moduleTitle=2019年ASCO：Umbralisib单药治疗边缘区淋巴瘤的阳性中期数据（UNITY-NHL试验）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=817a16e7558a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1493227, encodeId=da3b149322ef6, content=<a href='/topic/show?id=b46f12e81ed' target=_blank style='color:#2F92EE;'>#NHL#</a>, objectTitle=刘澎教授：不同机制的药物在NHL的研究进展, objectType=article, longId=166952, objectId=2ce016695233, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2ce016695233, replyNumber=0, likeNumber=128, createdTime=2019-05-29, rootId=0, userName=yzh402, userId=f7839003589, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2ce016695233, moduleTitle=刘澎教授：不同机制的药物在NHL的研究进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2ce016695233)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1493226, encodeId=936914932262a, content=<a href='/topic/show?id=b46f12e81ed' target=_blank style='color:#2F92EE;'>#NHL#</a>, objectTitle=不同机制的药物在NHL的研究进展, objectType=article, longId=166863, objectId=745e16686371, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=745e16686371, replyNumber=0, likeNumber=90, createdTime=2019-05-28, rootId=0, userName=yzh402, userId=f7839003589, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=745e16686371, moduleTitle=不同机制的药物在NHL的研究进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=745e16686371)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1493225, encodeId=c1e21493225ee, content=<a href='/topic/show?id=b46f12e81ed' target=_blank style='color:#2F92EE;'>#NHL#</a>, objectTitle=Blood：Parsaclisib，高选择性PI3Kδ抑制剂，可有效治疗复发性或难治性B细胞NHL, objectType=article, longId=163405, objectId=55c3163405ab, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=55c3163405ab, replyNumber=0, likeNumber=99, createdTime=2019-04-03, rootId=0, userName=yzh402, userId=f7839003589, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=55c3163405ab, moduleTitle=Blood：Parsaclisib，高选择性PI3Kδ抑制剂，可有效治疗复发性或难治性B细胞NHL, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=55c3163405ab)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1493224, encodeId=4528149322450, content=<a href='/topic/show?id=b46f12e81ed' target=_blank style='color:#2F92EE;'>#NHL#</a>, objectTitle=【2018 CSCO】黄慧强教授：CAR-T产品Yescarta在复发/难治NHL的治疗中处于领先地位, objectType=article, longId=149577, objectId=a4e21495e77d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a4e21495e77d, replyNumber=0, likeNumber=0, createdTime=2018-09-27, rootId=0, userName=yzh402, userId=f7839003589, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a4e21495e77d, moduleTitle=【2018 CSCO】黄慧强教授：CAR-T产品Yescarta在复发/难治NHL的治疗中处于领先地位, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a4e21495e77d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1493223, encodeId=de311493223ba, content=<a href='/topic/show?id=b46f12e81ed' target=_blank style='color:#2F92EE;'>#NHL#</a>, objectTitle=JCO：中位PFS 25.8月！GA101+苯达莫司汀方案可显著改善难治性惰性NHL患者生存, objectType=article, longId=147021, objectId=15b014e02131, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=15b014e02131, replyNumber=0, likeNumber=99, createdTime=2018-08-21, rootId=0, userName=yzh402, userId=f7839003589, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=15b014e02131, moduleTitle=JCO：中位PFS 25.8月！GA101+苯达莫司汀方案可显著改善难治性惰性NHL患者生存, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=15b014e02131)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1493222, encodeId=9328149322284, content=<a href='/topic/show?id=b46f12e81ed' target=_blank style='color:#2F92EE;'>#NHL#</a>, objectTitle=Blood：预注射多功能的抗CD19的嵌合抗原受体T细胞可改善NHL患者的临床预后, objectType=article, longId=140802, objectId=f297140802b9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f297140802b9, replyNumber=0, likeNumber=0, createdTime=2018-06-16, rootId=0, userName=yzh402, userId=f7839003589, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f297140802b9, moduleTitle=Blood：预注射多功能的抗CD19的嵌合抗原受体T细胞可改善NHL患者的临床预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f297140802b9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1493221, encodeId=c0de1493221cf, content=<a href='/topic/show?id=b46f12e81ed' target=_blank style='color:#2F92EE;'>#NHL#</a>, objectTitle=Am J Hematol：ROAD能否作为复发侵袭性NHL患者的治疗选择？, objectType=article, longId=119139, objectId=605f11913951, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=605f11913951, replyNumber=0, likeNumber=98, createdTime=2017-11-09, rootId=0, userName=yzh402, userId=f7839003589, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=605f11913951, moduleTitle=Am J Hematol：ROAD能否作为复发侵袭性NHL患者的治疗选择？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=605f11913951)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1493220, encodeId=521f1493220dc, content=<a href='/topic/show?id=b46f12e81ed' target=_blank style='color:#2F92EE;'>#NHL#</a>, objectTitle=ASH 2014：idelalisib治疗CLL和iNHL疗效初显, objectType=article, longId=44387, objectId=63784438e45, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=63784438e45, replyNumber=0, likeNumber=102, createdTime=2014-12-24, rootId=0, userName=yzh402, userId=f7839003589, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=63784438e45, moduleTitle=ASH 2014：idelalisib治疗CLL和iNHL疗效初显, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=63784438e45)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1493219, encodeId=db83149321912, content=<a href='/topic/show?id=b46f12e81ed' target=_blank style='color:#2F92EE;'>#NHL#</a>, objectTitle=吉利德idelalisib关键性II期iNHL试验取得积极数据, objectType=article, longId=27832, objectId=19052e832dd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=19052e832dd, replyNumber=0, likeNumber=121, createdTime=2013-12-12, rootId=0, userName=yzh402, userId=f7839003589, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=19052e832dd, moduleTitle=吉利德idelalisib关键性II期iNHL试验取得积极数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=19052e832dd)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

NHL

2020-05-29

梅斯管理员

#来那度胺# #NHL# #奥妥珠单抗#

【EClinicalMedicine】奥妥珠单抗联合来那度胺治疗复发难治性惰性NHL

2024-08-23发表于上海

梅斯管理员

#非霍奇金淋巴瘤# #NHL# #CAR-T治疗#

JAMA Oncol：综合放疗用于局限性NHL CAR-T桥接治疗的小型研究

2024-05-28发表于上海

梅斯管理员

#吉西他滨# #NHL# #BEAM/BEAC#

【Cancer Med】NHL自体移植前预处理，含吉西他滨方案与BEAM/BEAC无差异

2024-02-18发表于陕西省

梅斯管理员

#非霍奇金淋巴瘤# #NHL# #CAR-T#

【CII】赵明峰教授团队基于T细胞亚群开发预测CAR-T治疗r/r NHL反应的模型

2024-02-15发表于陕西省

yzh402

#NHL#

Oncologist:老年侵袭性非霍奇金淋巴瘤（NHL）的临床结局、治疗毒性和医疗保健利用

2021-08-15

yzh402

#NHL#

Blood：自体移植 or 异体移植，外周T-NHL患者到底该选谁？

2021-01-07

yzh402

#NHL#

Clin Cancer Res：JWCAR029可有效且安全治疗难治性B-NHL

2020-10-02

yzh402

#NHL#

Blood：Myc对采用EPOCH±Vorinostat治疗的HIV-NHLs的预后的影响

2020-06-03

yzh402

#NHL#

Blood：Ublituximab联合Umbralisib治疗复发性/难治性B细胞NHL和CLL的安全性评估

2019-10-04

yzh402

#NHL#

European Journal of Human Genetics：中国SNHL患者的综合遗传测试和变异解释

2019-10-03

yzh402

#NHL#

2019年ASCO：Umbralisib单药治疗边缘区淋巴瘤的阳性中期数据（UNITY-NHL试验）

2019-06-07

yzh402

#NHL#

刘澎教授：不同机制的药物在NHL的研究进展

2019-05-29

yzh402

#NHL#

不同机制的药物在NHL的研究进展

2019-05-28

yzh402

#NHL#

Blood：Parsaclisib，高选择性PI3Kδ抑制剂，可有效治疗复发性或难治性B细胞NHL

2019-04-03

yzh402

#NHL#

【2018 CSCO】黄慧强教授：CAR-T产品Yescarta在复发/难治NHL的治疗中处于领先地位

2018-09-27

yzh402

#NHL#

JCO：中位PFS 25.8月！GA101+苯达莫司汀方案可显著改善难治性惰性NHL患者生存

2018-08-21

yzh402

#NHL#

Blood：预注射多功能的抗CD19的嵌合抗原受体T细胞可改善NHL患者的临床预后

2018-06-16

yzh402

#NHL#

Am J Hematol：ROAD能否作为复发侵袭性NHL患者的治疗选择？

2017-11-09

yzh402

#NHL#

ASH 2014：idelalisib治疗CLL和iNHL疗效初显

2014-12-24

yzh402

#NHL#

吉利德idelalisib关键性II期iNHL试验取得积极数据

2013-12-12